Description:
Cisplatin analogs for treating cancers
The Invention
Platinum-based drugs, such as Cisplatin, are commonly prescribed drugs for cancer treatment. However, these drugs are limited by a narrow spectrum of activity, treatment resistance, and can include toxic side effects.
This invention introduces a series of novel compounds and methods of treatment comprising platinum Pt(IV) complexes with a substituted 2,2-bypyridine ring structure. These complexes display anti-proliferative activity against cancer cells as well as
reduced toxic side effects.
Key Benefits
- More effective than unmodified cisplatin
- Reduced toxic side effects
- Can be used in combination with other drugs for
treatment, prevention, amelioration or reduction of risk for
cancer
Applications
- Cell therapy
- Cancer treatment
Market Opportunity
The American Cancer Society estimated 1.9 million new cancer cases diagnosed and 609,360 deaths from cancer in 2022. It is estimated 2,286,300 new cases will be diagnosed in 2050, a 20% increase from 2022. The global cancer treatment market was
valued at $166.5 billion in 2021 and is expected to grow at a CAGR of 9.1% to $335.06 billion by 2030.
There is a need to develop analogues that can be more effective and less toxic than the widely used Cisplatin - expected to reach a market size of $661 million by 2027. Platinum based cancer based cancer drugs as a whole are expected to surpass $1.81 billion by 2026. Toxic side effects are a substantial hurdle to overcome. The current platinum based compounds have been shown to be more effective than Cisplatin and with reduced toxic side effects.
Development and Intellectual Property Status
US Patent Issued 6/11/2019
Looking for licensing partner for additional development, clinic
trials and commercialization